This study by WashU Researchers shows that a novel blood-based digital PCR test can detect when treatment is failing a median of three months before standard of care testing identifies treatment failure —enough lead time to change therapy and potentially improve outcomes for these patients. Findings of this study have been published in Haematologica.
Noor, A., Cao, X., Cox, M.J., Kuthuru, T., Ferraro, F., Spencer, D.H., Oh, S.T., Challen, G.A. and Young, A.L., 2026. Non-invasive personalized fusion measurable residual disease detection in acute myeloid leukemia using digital PCR. Haematologica, Advance online publication. DOI: https://doi.org/10.3324/haematol.2026.301243.